肺癌活检组织中Polo样激酶-1mRNA水平检测的临床意义

Measurement of the mRNA level of Polo-like kinase 1 in bronchoscopic bioptic specimens by realtime quantitative PCR

目的探讨实时荧光定量-聚合酶链反应(RFQ-PCR)检测肺癌活检组织 Polo 样激酶-1(PLK1)mRNA 水平,及其与肺癌临床病理分期、分型的相关性。方法对69份肺癌、28份肺良性疾病患者的纤维支气管镜活检标本,采用 RFQ-PCR 检测 PLK1和 GAPDH 荧光强度,并绘制曲线,计算出循环数阈值(Ct),相同组织中 PLK1和 GAPDH 的初始模板量的比值为2^(CtGAPDH-CtPLK1),同时以此值作为 PLK1 mRNA 水平的相对定量指标进行标本检测结果评价。结果肺癌组 PLK1 mRNA 水平为0.124±0.194,肺良性疾病组为0.037±0.042,两者差异有统计学意义(P=0.03)。而其在各病理类型和不同 TNM 分期之间的差异均无统计学意义(P>0.05),仅小细胞肺癌的表达水平略高(0.191±0.275)。结论 RFQ-PCR 测定纤维支气管镜活检标本中 PLK1基因表达增高与肺癌的发生存在一定关系,并且可能成为肺癌检测的一个肿瘤标志。

Objective To establish the real-time fluorescent quantitative PCR （RFQ-PCR） for measurement of PLK1 mRNA level in bronchoscopic bioptic specimens betweerl lung cancers and pulmonary benign diseases, and to assess its relation to TNM staging and pathological classification. Methods The patients was composed of 69 primary lung cancers and 28 pulmonary benign diseases. PLK1 and GADPH gene of all bronchoscopic bioptic specimens were detected by RFQ-PCR. According to the fluorescent intensity curves, the determination of the Ct （Cycle threshold value ） was reported. The value of 2^CtGAPDH-CtPLK1 was presented the relative quantitative level of PLK1 mRNA. Results Elevated expression of PLK1 mRNA was observed in lung cancer specimens （ 0. 124 ± 0. 194 ） corapared with benign diseases （0. 037 ± 0. 042 ）, statistically significant associations being evident （ P = 0. 03 ）, but non-significant associations with pathological classification （ P 〉 0. 05） and the TNM staging （ P = 0. 55）. A mild elevated compared other pathological classification was found in small cell lung cancer （0. 191 ± 0. 275 ）. Conclusions The results showed that RFQ-PCR was suitable for measurement of the mRNA level of PLK1 in bronchoscopic bioptic specimens. This study suggest elevated expression of PLK1 might play a important role in development of lung cancer, so that PLK1 might be a potential tumor marker for Lung cancers. Advanced studies will be needed to clarify that PLK1 mRNA level do not relate to TNM staging and pathological classification.